Cibus Q3 net loss $201.5M on $181.4M goodwill impairment; cash runway into late Q1 2025

Cibus, Inc.

2024-Q3 EPS reported -$10.33 revenue$3,050,000

Net loss $201.5M ($7.63/sh) vs $34.5M ($1.59/sh) YoY; includes $181.4M non-cash goodwill impairment.
Cash $28.8M; expects funding into late Q1 2025 without additional financing; board evaluating strategic alternatives.
Initiating $10M annualized cost savings, reducing monthly cash usage ~20%; one-time severance charge in Q4.
Rice platform: agreements with 4 seed companies, successful HT3 field trials, stacked gene-edited trait results.
Soybean platform expected operational by year-end 2024; Sclerotinia resistance field trial positive for second mode of action.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.